A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Bioneb Pvt Secures GBP £ 220 Million Capital Commitment From the Gem Group

October 26, 2020

Bioneb Pvt (Bioneb) announced that it has signed an agreement with GEM Global Yield LLC SCS (“GEM“), the New York-based private alternative investment group to provide Bioneb up to GBP £ 220 million over a 36-month term.

Bioneb will use the funds to continue its research and development of its FDA-approved ultrasonic vibrating mesh drug delivery devices, medical formulations and FDA clinical trials. The company will also increase the manufacturing of the devices at the FDA-approved Vietnamese and Taipei facilities. Simultaneously there will be an increase in the production, distribution, and marketing of the formulations at the Netherlands, Canadian and Californian facilities.

The company will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The company will issue warrants to GEM to purchase up to nine point nine percent (9.9%) of the outstanding common stock of the company on a fully diluted basis. The warrants will have an exercise price per share equal to the pro-rata portion of GBP 300 Million valuation for the company. Bioneb Pvt will pay a fee equal to two percent (2%) of the size of capital commitment within a period of twelve months.

“This agreement with GEM helps to secure funding for continued growth and development of the company as we attempt to bring to market our breakthrough Covid suppressant formulation which is having remarkable results in suppressing and eliminating the Covid Virus if used in the early stages of any infection. The proven results, case studies, time-kill graphs, and curves show that Bioneb’s patent-pending anti-viral formulation eliminates any virus and bacteria when inhaled with the drug delivery device or disbursed into built in environments such as schools, offices or mass transport systems using the same technology in a sub-micron diffuser distribution unit,” stated Mr. Nick Havercroft, CEO, and Founder of Bioneb Pvt.

SourceBioneb
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy